Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Keros Therapeutics, Inc is a biotechnology business based in the US. Keros Therapeutics shares (KROS) are listed on the NASDAQ and all prices are listed in US Dollars. Keros Therapeutics employs 32 staff and has a trailing 12-month revenue of around USD$2.5 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
52-week range | USD$19.1 - USD$86.8 |
---|---|
50-day moving average | USD$65.8979 |
200-day moving average | USD$58.9129 |
Wall St. target price | USD$86.25 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | N/A |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Revenue TTM | USD$2.5 million |
---|---|
Gross profit TTM | USD$-7,379,000 |
Return on assets TTM | -34.41% |
Return on equity TTM | 0% |
Profit margin | 0% |
Book value | N/A |
Market capitalisation | USD$1.5 billion |
TTM: trailing 12 months
There are currently 618,584 Keros Therapeutics shares held short by investors – that's known as Keros Therapeutics's "short interest". This figure is 2.2% down from 632,285 last month.
There are a few different ways that this level of interest in shorting Keros Therapeutics shares can be evaluated.
Keros Therapeutics's "short interest ratio" (SIR) is the quantity of Keros Therapeutics shares currently shorted divided by the average quantity of Keros Therapeutics shares traded daily (recently around 135654.38596491). Keros Therapeutics's SIR currently stands at 4.56. In other words for every 100,000 Keros Therapeutics shares traded daily on the market, roughly 4560 shares are currently held short.
However Keros Therapeutics's short interest can also be evaluated against the total number of Keros Therapeutics shares, or, against the total number of tradable Keros Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Keros Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Keros Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0607% of the tradable shares (for every 100,000 tradable Keros Therapeutics shares, roughly 61 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Keros Therapeutics.
Find out more about how you can short Keros Therapeutics stock.
We're not expecting Keros Therapeutics to pay a dividend over the next 12 months.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.